Special Medical Liaisons Are No Back Door To Off-Label Promotion - Experts
This article was originally published in The Gray Sheet
Executive Summary
Specialized medical liaisons can help companies navigate scientific discussions on off-label product applications, but are not immune to government enforcement efforts when they cross the line, experts caution
You may also be interested in...
Off-Label Questions, Online: FDA Explains How To Handle Them
FDA draft guidance weighs in on web communications, saying that firms must answer off-label-information questions privately, even if the questions arise in a public online forum.
Stryker Unit Charged With Fraud, Misbranding For Illegal Marketing Scheme
Stryker's biotech division and four former and current executives face charges of wire fraud, conspiracy, device misbranding and false statements related to the marketing of its OP-1 orthopedic bone growth biologic/device combination products
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.